99 related articles for article (PubMed ID: 28293974)
1. Treatment of hepatitis C virus infection: updated Swedish Guidelines 2016.
Lagging M; Wejstål R; Norkrans G; Karlström O; Aleman S; Weiland O; Castedal M; Westin J;
Infect Dis (Lond); 2017 Aug; 49(8):561-575. PubMed ID: 28293974
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C virus infection: Are there still specific problems with genotype 3?
Gondeau C; Pageaux GP; Larrey D
World J Gastroenterol; 2015 Nov; 21(42):12101-13. PubMed ID: 26576095
[TBL] [Abstract][Full Text] [Related]
3. Genotype 3 Infection: The Last Stand of Hepatitis C Virus.
Chan A; Patel K; Naggie S
Drugs; 2017 Feb; 77(2):131-144. PubMed ID: 28074358
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus: life cycle in cells, infection and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy.
Dustin LB; Bartolini B; Capobianchi MR; Pistello M
Clin Microbiol Infect; 2016 Oct; 22(10):826-832. PubMed ID: 27592089
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of viral hepatitis.
Easterbrook PJ; Roberts T; Sands A; Peeling R
Curr Opin HIV AIDS; 2017 May; 12(3):302-314. PubMed ID: 28306597
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C Virus Diagnosis and the Holy Grail.
Applegate TL; Fajardo E; Sacks JA
Infect Dis Clin North Am; 2018 Jun; 32(2):425-445. PubMed ID: 29778264
[TBL] [Abstract][Full Text] [Related]
7. Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: A prospective study.
Boglione L; Mornese Pinna S; De Nicolò A; Cusato J; Cariti G; Di Perri G; D'Avolio A
J Viral Hepat; 2017 Oct; 24(10):850-857. PubMed ID: 28345206
[TBL] [Abstract][Full Text] [Related]
8. Recommendations for the treatment of hepatitis C in 2017.
; Halota W; Flisiak R; Juszczyk J; Małkowski P; Pawłowska M; Simon K; Tomasiewicz K
Clin Exp Hepatol; 2017 Jun; 3(2):47-55. PubMed ID: 28856290
[TBL] [Abstract][Full Text] [Related]
9. American Gastroenterological Association Institute Clinical Practice Update-Expert Review: Care of Patients Who Have Achieved a Sustained Virologic Response After Antiviral Therapy for Chronic Hepatitis C Infection.
Jacobson IM; Lim JK; Fried MW
Gastroenterology; 2017 May; 152(6):1578-1587. PubMed ID: 28344022
[TBL] [Abstract][Full Text] [Related]
10. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses.
Welzel TM; Bhardwaj N; Hedskog C; Chodavarapu K; Camus G; McNally J; Brainard D; Miller MD; Mo H; Svarovskaia E; Jacobson I; Zeuzem S; Agarwal K
J Hepatol; 2017 Aug; 67(2):224-236. PubMed ID: 28343981
[TBL] [Abstract][Full Text] [Related]
11. Viral and host factors associated with outcomes of hepatitis C virus infection (Review).
Yan Z; Wang Y
Mol Med Rep; 2017 May; 15(5):2909-2924. PubMed ID: 28339063
[TBL] [Abstract][Full Text] [Related]
12. Increased Mortality Among Persons With Chronic Hepatitis C With Moderate or Severe Liver Disease: A Cohort Study.
Cepeda JA; Thomas DL; Astemborski J; Sulkowski MS; Kirk GD; Mehta SH
Clin Infect Dis; 2017 Jul; 65(2):235-243. PubMed ID: 28329108
[TBL] [Abstract][Full Text] [Related]
13. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.
Falade-Nwulia O; Suarez-Cuervo C; Nelson DR; Fried MW; Segal JB; Sulkowski MS
Ann Intern Med; 2017 May; 166(9):637-648. PubMed ID: 28319996
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
Cho BW; Kim SB; Song IH; Lee SH; Kim HS; Lee TH; Kang YW; Kim SH; Lee BS; Chae HB
Clin Mol Hepatol; 2017 Mar; 23(1):51-56. PubMed ID: 28297836
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
Saint-Laurent Thibault C; Moorjaney D; Ganz ML; Sill B; Hede S; Yuan Y; Gorsh B
J Med Econ; 2017 Jul; 20(7):692-702. PubMed ID: 28294645
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis.
Grebely J; Applegate TL; Cunningham P; Feld JJ
Expert Rev Mol Diagn; 2017 Dec; 17(12):1109-1115. PubMed ID: 29088981
[TBL] [Abstract][Full Text] [Related]
17. Recommendations for the treatment of hepatitis B in 2017.
; Flisiak R; Halota W; Jaroszewicz J; Juszczyk J; Małkowski P; Pawłowska M; Piekarska A; Simon K; Tomasiewicz K; Wawrzynowicz-Syczewska M
Clin Exp Hepatol; 2017 Jun; 3(2):35-46. PubMed ID: 28856289
[TBL] [Abstract][Full Text] [Related]
18. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients.
Belli LS; Duvoux C; Berenguer M; Berg T; Coilly A; Colle I; Fagiuoli S; Khoo S; Pageaux GP; Puoti M; Samuel D; Strazzabosco M
J Hepatol; 2017 Sep; 67(3):585-602. PubMed ID: 28323126
[TBL] [Abstract][Full Text] [Related]
19. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.
Kwo PY; Poordad F; Asatryan A; Wang S; Wyles DL; Hassanein T; Felizarta F; Sulkowski MS; Gane E; Maliakkal B; Overcash JS; Gordon SC; Muir AJ; Aguilar H; Agarwal K; Dore GJ; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
J Hepatol; 2017 Aug; 67(2):263-271. PubMed ID: 28412293
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C infection: Updates on treatment guidelines.
Pozza R; Hill C; Hefner AM; Vawter B; Hassanein T
Nurse Pract; 2017 May; 42(5):14-23. PubMed ID: 28379888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
